Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Income Statements
Fiscal Year end for Puma Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 236 | 228 | 253 | 225 | 272 |
Cost Of Goods | 63 | 55 | 64 | 39 | 37 |
Gross Profit | 173 | 173 | 189 | 186 | 235 |
Selling & Adminstrative & Depr. & Amort Expenses | 140 | 149 | 188 | 216 | 275 |
Income After Depreciation & Amortization | 33 | 24 | 1 | -30 | -39 |
Non-Operating Income | 3 | -12 | -17 | -15 | -21 |
Interest Expense | 13 | 12 | 13 | 14 | 15 |
Pretax Income | 23 | 0 | -29 | -60 | -76 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 22 | 0 | -29 | -60 | -76 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 22 | 0 | -29 | -60 | -76 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 44 | 33 | 12 | -20 | -31 |
Depreciation & Amortization (Cash Flow) | 12 | 9 | 11 | 10 | 8 |
Income After Depreciation & Amortization | 33 | 24 | 1 | -30 | -39 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 47.55 | 44.93 | 40.64 | 39.58 | 38.77 |
Diluted EPS Before Non-Recurring Items | 0.45 | 0.00 | -0.72 | -1.52 | -1.95 |
Diluted Net EPS (GAAP) | 0.45 | 0.00 | -0.72 | -1.52 | -1.95 |
Fiscal Year end for Puma Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 47.08 | 43.77 | 72.18 | 56.12 | 54.57 |
Cost Of Goods | 10.66 | 10.73 | 24.32 | 13.28 | 11.86 |
Gross Profit | 36.43 | 33.04 | 47.86 | 42.83 | 42.71 |
SG&A, R&D, and Dept/Amort Expenses | 38.60 | 35.34 | 33.05 | 34.25 | 37.82 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.17 | -2.30 | 14.81 | 8.58 | 4.89 |
Non-Operating Income | 1.40 | 1.06 | 1.36 | 0.76 | 0.75 |
Interest Expense | 3.37 | 3.36 | 3.35 | 3.34 | 3.33 |
Pretax Income | -4.15 | -4.60 | 12.80 | 6.01 | 2.31 |
Income Taxes | 0.38 | 0.22 | 0.54 | 0.21 | 0.19 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.53 | -4.82 | 12.27 | 5.80 | 2.13 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.53 | -4.82 | 12.27 | 5.80 | 2.13 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 48.29 | 48.19 | 48.04 | 47.82 | 47.20 |
Diluted EPS Before Non-Recurring Items | -0.09 | -0.10 | 0.26 | 0.12 | 0.05 |
Diluted Net EPS (GAAP) | -0.09 | -0.10 | 0.25 | 0.12 | 0.05 |